GlassScriptPhysician profile
Melissa D Reigle
NPI 1124013313
$3,018.64
in general payments reported to CMS, 2019-2025
28 companies · $298 in 2025
The $298 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $364 · 2020: $271 · 2021: $601 · 2022: $430 · 2023: $598 · 2024: $456 · 2025: $298.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,352.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,352.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $479.92 | 2019-2023 | Myrbetriq |
| Rochester Medical Corporation | $389.88 | 2019-2022 | |
| C. R. Bard, INC. & Subsidiaries | $362.58 | 2019-2023 | Bard Urinary Drainage Bag |
| Dendreon Pharmaceuticals LLC | $242.28 | 2024-2025 | Provenge |
| Axonics, INC. | $240.32 | 2021-2024 | Axonics, Bulkamid |
| Sumitomo Pharma America, INC. | $184.15 | 2023-2024 | Gemtesa, Orgovyx |
| Tolmar, INC. | $148.94 | 2023-2025 | Eligard, Jatenzo |
| Abbvie INC. | $140.24 | 2019-2025 | |
| Tolmar Pharmaceuticals, INC. | $118.29 | 2020-2022 | |
| Myovant Sciences INC. | $117.67 | 2021-2022 | |
| Urogen Pharma, INC. | $64.91 | 2020-2023 | Jelmyto |
| Coloplast Corp | $64.90 | 2019-2025 | |
| Caldera Medical, INC | $57.29 | 2022 | |
| Urovant Sciences INC | $48.38 | 2021-2022 | |
| Blue Earth Diagnostics | $45.88 | 2023 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $44.75 | 2019-2024 | Adstiladrin |
| Genzyme Corporation | $41.76 | 2022-2023 | |
| Dentsply Ih INC. | $33.24 | 2019-2020 | |
| Antares Pharma, INC. | $29.16 | 2021 | |
| Endo Pharmaceuticals INC. | $29.10 | 2019-2024 | Xiaflex |
| Astrazeneca Pharmaceuticals LP | $20.13 | 2022 | |
| Telix Pharmaceuticals | $20.13 | 2024 | Illuccix |
| Allergan, INC. | $18.87 | 2020 | |
| Janssen Biotech, INC. | $18.70 | 2025 | Erleada |
| Sun Pharmaceutical Industries INC. | $17.90 | 2022 | |
| Convatec INC. | $13.95 | 2022 | |
| Boston Scientific Corporation | $12.82 | 2021 | |
| Clarus Therapeutics INC. | $12.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Reigle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.